Sequential neurodegenerative trajectories across the onset of mild parkinsonian signs in isolated REM sleep behavior disorder: a longitudinal multimodal imaging study
Objective: To demonstrate the neurodegeneration status implied by mild parkinsonian signs (MPS) in patients with isolated REM sleep behavior disorder (iRBD) by analyzing longitudinal clinical…Early Complement Activation Prunes Inhibitory Synapses in Prodromal Synucleinopathy Independent from Lewy Pathology.
Objective: To identify early molecular and cellular changes associated with dopaminergic neuron vulnerability and synuclein pathology across different disease contexts. Background: Parkinson’s disease (PD) is…Traumatic Brain Injury Exacerbates Parkinsonian Neurodegeneration Through Alpha Synuclein Dysregulation
Objective: This study aimed to determine whether repetitive mild traumatic brain injury exacerbates Parkinsonian neurodegeneration and promotes alpha synuclein pathology in an experimental model. Background:…Efficacy of Stimulant Use for Cognitive Fluctuations in Lewy Body Dementia: A Case Study
Objective: To evaluate the effectiveness of stimulants in reducing cognitive fluctuations in Lewy Body Dementia (LBD). Background: Lewy Body Dementia (LBD) is the 2nd most…Sex differences in regional densities of Lewy body pathology
Objective: To assess sex differences in regional Lewy body pathology densities and their clinical correlations in cases with Lewy body (LB) pathology at autopsy. Background:…Lewy Pathology in the Peripheral Nervous System of SNCA Duplication
Objective: This study aimed to investigate the degree, distribution, and biochemical profile of phosphorylated α-synuclein (p-α-syn) in the peripheral nervous system of patients with SNCA…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body
Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia
Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT2A Inverse Agonist, in Adults With Lewy Body Dementia Psychosis
Objective: To present the design for a study of ACP-204 efficacy and safety in adults with Lewy body dementia psychosis (LBDP), including Parkinson’s disease dementia…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »